Together we will find a cure Donate
Together we will find a cure Donate


National brain tumour research funding needs to increase to £35 million a year

Paying tribute to Peter

Peter Bulbeck, co-founder of our sister charity brainstrust, has passed away.

The charity has announced that Peter died peacefully at home in Cowes on the Isle of Wight on Thursday 31st August.

Alongside his wife, Helen, and a small group of family Trustees, Peter founded brainstrust in 2006 following his step-daughter Meg’s shock brain tumour diagnosis.

The charity succeeded in its early goals of raising funds and securing treatment to save Meg’s life. It has since gone from strength to strength, and now works nationally to support thousands of people navigate a brain tumour diagnosis, to inform policy and practice at the highest levels and to bring people with a brain tumour closer to research.

In a tribute to Peter published on brainstrust’s website, the charity wrote: “Peter’s commitment and contribution to brainstrust’s growth has been nothing short of astonishing with his influence fostering a great team culture, impeccable governance and first-class financial track-record.

“Peter remained a close friend and colleague to us all and our community until just days before his death. He held a vital role as head of governance, compliance, HR and was our Chief Financial Officer.”

Our Co-founder and now Trustee, Sue Farrington Smith MBE, said: “I have known Helen and Peter for many years now and was deeply saddened to learn of Peter’s passing. The brain tumour community has lost a wonderful advocate. Peter’s legacy will live on through the work brainstrust is doing to support everyone with this devastating disease to feel less afraid, less alone and more in control.

“I and all at Brain Tumour Research send our deepest condolences at this difficult time to Helen, Will, Meg and all those who knew and loved Peter.”

Related reading:

If you found this story interesting or helpful, sign up to our weekly e-news and keep up to date with all the latest from Brain Tumour Research.